Portal builds a proprietary mechanoporation-based platform to enable efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across diverse cell types and workflows. The company targets applications across novel drug discovery workflows, multi-perturbation AI data generation, and next-generation cell therapies, and integrates with high-throughput robotics and GMP manufacturing systems. Portal reports commercial traction with more than 100 customer sites, including public collaborations or use by Microsoft, Merck, AbbVie, Mass General Brigham, the Ragon Institute, and Purdue University. Use cases highlighted include high-throughput, physiologically relevant screening, generation of model-training biological data, and same-day circRNA-based multifunctional CAR-T production at the point of care. DARPA has expanded an initial $8M contract and is supporting commercialization through its EEI program, underscoring validation for Portal's point-of-care cell therapy manufacturing efforts. The company states it has achieved meaningful commercial revenue and technical validation from large pharma and academic partners.

Total raised

$21M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2026